A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer
- 1 August 1996
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 74 (3) , 460-462
- https://doi.org/10.1038/bjc.1996.382
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive daysEuropean Journal Of Cancer, 1994
- Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1994
- Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1994
- Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I studyInvestigational New Drugs, 1992
- Action of 2',2'-difluorodeoxycytidine on DNA synthesis.1991
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- EVALUATION OF THE ANTITUMOR-ACTIVITY OF GEMCITABINE (2',2'-DIFLUORO-2'-DEOXYCYTIDINE)1990
- COMPARISON OF THE CELLULAR PHARMACOKINETICS AND TOXICITY OF 2',2'-DIFLUORODEOXYCYTIDINE AND 1-BETA-D-ARABINOFURANOSYLCYTOSINE1988
- Reporting results of cancer treatmentCancer, 1981